However, there is considerable inter-patient variation and the low number of AML patient samples does not reveal a robust signature for a distinct repeat type that would consistently be derepressed in AML patient samples vs. CD34 + healthy control samples. This evidence concerns the gene CD34 and acute myeloid leukemia.